Pathstone Holdings
LXRX icon

Pathstone Holdings’s Lexicon Pharmaceuticals LXRX Stock Holding History

Pathstone Holdings’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.9K Buy
29,969
+195
+0.7% +$380 ﹤0.01% 2299
2026
Q1 		$46.4K Sell
29,774
-195
-0.7% -$284 ﹤0.01% 2187
2025
Q4 		$34.5K Sell
29,969
-239
-0.8% -$328 ﹤0.01% 2201
2025
Q3 		$40.8K Buy
30,208
+167
+0.6% +$190 ﹤0.01% 2313
2025
Q2 		$28.4K Sell
30,041
-1,356
-4% -$879 ﹤0.01% 2162
2025
Q1 		$14.5K Sell
31,397
-22,654
-42% -$14.3K ﹤0.01% 2211
2024
Q4 		$39.9K Sell
54,051
-4,908
-8% -$5.92K ﹤0.01% 2272
2024
Q3 		$92.6K Sell
58,959
-1,079
-2% -$1.92K ﹤0.01% 2245
2024
Q2 		$101K Sell
60,038
-2,687
-4% -$4.82K ﹤0.01% 2225
2024
Q1 		$151K Buy
62,725
+28,280
+82% +$60.8K ﹤0.01% 2187
2023
Q4 		$52.7K Buy
+34,445
New +$41K ﹤0.01% 2167

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Pathstone Holdings's LXRX Position: Q2 2026 in Review

Pathstone Holdings increased its Lexicon Pharmaceuticals (LXRX) stake by 0.65% in Q2 2026, buying an estimated $380 and bringing the position to 29,969 shares worth $71.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2299.

Pathstone Holdings first reported a position in LXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $151K in Q1 2024. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Pathstone Holdings held 29,969 shares of Lexicon Pharmaceuticals worth $71.9K as of Q2 2026.
  • Pathstone Holdings bought 195 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $380.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2299 holding.
  • Pathstone Holdings first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Lexicon Pharmaceuticals position peaked at $151K in Q1 2024.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.